Inquis Medical, a medical device company pioneering advanced treatments for venous thromboembolic disease, today announced the U.S. commercial launch of the latest AVENTUS™ Catheter, designed to provide physicians with 360° sweeping directional aspiration for clot removal within the vasculature. Austin Bourgeois, MD, performed the first-in-human pulmonary embolism (PE) procedure using the new catheter at Huntsville Hospital in Huntsville, Alabama.

AVENTUS is the first and only thrombectomy system to offer physicians 360° directional aspiration, real-time TrueClot™ tissue sensing, and autologous blood return in a single platform. With the turn of a knob, physicians can rotate the catheter and direct the angled aspiration tip toward obstructive clot without dilator exchanges, accessory catheters, or device repositioning.

Inquis Medical received FDA clearance for the AVENTUS Thrombectomy System to treat PE in June 2025 and expanded the platform with 510(k) clearance for the newest AVENTUS Catheter in July 2026.

“The latest AVENTUS Catheter brings a new level of control to navigating the complex anatomy of the pulmonary vasculature,” said Dr. Bourgeois, a vascular and interventional radiologist at Huntsville Hospital. “The system made it easy to direct the aspiration tip toward the clot, while tissue sensing helped me distinguish clot from vessel wall. These features together made clot removal more targeted and efficient, and I was able to move through the branches of the pulmonary arteries with agility. In my first case with the new AVENTUS Catheter, I saw firsthand the precise control it offers, which is exactly what we need in challenging PE cases with complex anatomy.”

The catheter pairs with the recently launched AVENTUS Introducer Sheath, which provides controlled hemostasis across device sizes and facilitates effortless blood return. Together with integrated autologous blood return, the new catheter and sheath expand the AVENTUS Thrombectomy System into a comprehensive access-to-aspiration platform for venous thrombectomy.

Vahid and Mojgan Saadat, Inquis Medical’s co-CEOs, added in a joint statement, “The commercial launch of the AVENTUS Catheter expands our purpose-built VTE portfolio, reinforcing our commitment to physician-centric technologies that streamline complex procedures and elevate patient care.”

About AVENTUS™

The AVENTUS Thrombectomy System is designed to address the challenges of thrombectomy procedures, including those for pulmonary embolism. The platform simplifies PE thrombectomy by combining real-time tissue identification, directional aspiration, and in-line blood return, maximizing clot-removal efficiency while minimizing blood loss. The new 24F Catheter extends this capability with full 360° directionality.

At the core of the system is TrueClot Sensing, a proprietary tissue-sensing technology that gives operators real-time feedback to differentiate between blood, clot, and vessel wall. This intraprocedural insight, combined with an atraumatic dilator tip and integrated navigation catheter, supports an intelligent and efficient intervention designed to deliver more predictable outcomes.

The AVENTUS Thrombectomy System is indicated for the non-surgical removal of emboli and thrombi from blood vessels; for the injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel; and for autologous blood transfusion. It is intended for use in the peripheral vasculature and for the treatment of pulmonary embolism.

About Inquis Medical, Inc.

Inquis Medical is a commercial-stage medical device company pioneering advanced, integrated technologies for venous thromboembolic disease. Dedicated to supporting interventional physicians and improving patient outcomes, Inquis Medical develops innovative thrombectomy solutions designed to enhance procedural control, optimize clot removal, and advance patient care. For more information, visit www.inquismedical.com.

For more information, visit our website or follow us on LinkedIn.

Media gallery

About The Author